Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights
into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs …

Assessments of disease progression and response to therapies in Duchenne muscular
dystrophy (DMD) patients remain challenging. Current DMD patient assessments include …

It is expected that serum protein biomarkers in Duchenne muscular dystrophy (DMD) will
reflect disease pathogenesis, progression and aid future therapy developments. Here, we …

Despite the recent progress in the broad‐scaled analysis of proteins in body fluids, there is
still a lack in protein profiling approaches for biomarkers of rare diseases. Scarcity of …

Purpose To identify and validate serum biomarkers for the progression of D uchenne
muscular dystrophy (DMD) using a MS‐based bottom‐up pipeline. Experimental design We …

Numerous biomarkers have been unveiled in the rapidly evolving biomarker discovery field,
with an aim to improve the clinical management of disorders. In rare diseases, such as …

Duchenne muscular dystrophy (DMD) is a neuromuscular disease characterized by
progressive weakness of the skeletal and cardiac muscles. This X-linked disorder is caused …

The primary cause of Duchenne muscular dystrophy (DMD) is a mutation in the dystrophin
gene, leading to absence of the corresponding protein, disruption of the dystrophin …

Background Identifying translatable, non-invasive biomarkers of muscular dystrophy that
better reflect the disease pathology than those currently available would aid the …

The primary cause of Duchenne muscular dystrophy (DMD) is a mutation in the dystrophin
gene leading to the absence of the corresponding RNA transcript and protein. Absence of …